Here is the counterintuitive truth that surprises most GLP-1 users when they apply for life insurance: the weight loss you worked for — and the medication that helped you lose it — does not automatically improve your application. In some cases, an underwriter looking at your file will see your rapid weight loss as a red flag, add a significant portion of that weight back into their risk calculation, and rate you higher than you expected. Or they will focus almost entirely on the underlying condition your GLP-1 was prescribed to treat, and rate you on that.
This is not a reason to avoid applying. It is a reason to understand how the process works before you walk into it unprepared. With approximately 55 million Americans now prescribed GLP-1 medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others — life insurance underwriting for this population is one of the fastest-changing areas of the industry in 2026. The guidance below reflects how major carriers are evaluating these applications right now.
Yes, you can get life insurance while taking a GLP-1 medication. Whether you get it at a preferred rate, a standard rate, or a rated (higher premium) policy depends almost entirely on the condition being treated, how well it is controlled, and how long you have been on a stable, compliant course of treatment — not on the medication itself.
What Underwriters Actually See When You Disclose a GLP-1
When your prescription for Ozempic, Wegovy, or Mounjaro appears on your application — either because you disclosed it or because the underwriter pulled your pharmacy history through the MIB (Medical Information Bureau) — they are simultaneously reading two things.
First: why are you on it? Semaglutide is FDA-approved for type 2 diabetes (as Ozempic) and for weight loss with cardiovascular risk factors (as Wegovy). Tirzepatide is approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). An underwriter seeing your GLP-1 prescription will check your diagnosis codes to understand which condition is being treated. A diabetes diagnosis carries different underwriting weight than an obesity diagnosis with no other conditions, and both carry different weight than a patient on a GLP-1 purely for cardiovascular risk reduction following the SELECT trial data.
Second: is it working? They will look at your most recent lab values — A1C for diabetic patients, blood pressure, LDL cholesterol, and your weight trend over time. A GLP-1 user with a steadily improving A1C, normalising blood pressure, and a consistent prescription refill history presents a fundamentally different risk profile than someone whose labs show the medication is not producing improvement.
The prescription itself is a data point. The underlying condition and its trajectory are the actual underwriting factors.
The Rapid Weight Loss Problem — And Why Underwriters Add Weight Back
This is the part that surprises people most. If you have lost 40, 50, or 80 pounds on a GLP-1 medication, you might expect underwriters to reward you. Instead, many carriers will add a significant portion of that weight back into their calculation — in many cases, up to half the lost weight.
The reason traces directly to clinical data. The landmark STEP 1 trial extension, published in 2022 by Wilding and colleagues, found that participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide. Underwriters know this. They are pricing 20- and 30-year policies on the assumption that the medication may not continue indefinitely — and that the underlying risk profile could return to baseline if it stops.
Traditional life insurance underwriting was built on a simple premise: your weight today tells us something about your long-term health risk. GLP-1 medications introduce a confounding variable. The weight on the scale today may not reflect the body’s underlying metabolic state if the drug stopped. As a result, some underwriters use a “stabilisation period” approach: they will rate you at your current weight only after you have maintained that weight consistently for 12 to 24 months on the medication. Before that window, they may add back a portion of the lost weight.
If you started Ozempic six months ago and lost 55 pounds, an underwriter may evaluate you as though you weigh 27 to 30 pounds more than you currently do. This does not change the outcome for most applicants — but it can push you from a preferred rate class to a standard rate class, or from standard to rated, in the early months of treatment.
What Munich Re’s Landmark Study Found — And What It Means for You
In early 2026, Munich Re published an analysis of 41 million insured lives covering the period from 2015 through January 2025. The study found that consistent users of GLP-1 agonists showed up to a 20% reduction in major cardiovascular events and lower all-cause mortality compared to non-users with similar underlying conditions.
This is significant for two reasons. First, it validates what the SELECT cardiovascular trial showed in 2023 — that these medications do more than manage weight or blood sugar, they appear to reduce mortality risk independent of those effects. Second, it is beginning to change how the most forward-looking carriers evaluate GLP-1 users who have been on treatment consistently for more than 12 months.
As of mid-2026, the industry has not standardised its response to this data. Some carriers are already adjusting their underwriting manuals to treat long-term GLP-1 users more favourably. Others are still applying the weight-add-back formula regardless. This variation across carriers is the core reason why working with an impaired risk specialist — someone who knows which carriers are ahead of the curve on this data — can make a meaningful difference in your outcome.
How Your Underlying Condition Shapes the Application More Than the Drug
The GLP-1 medication on your prescription tells the underwriter where to look. The underlying condition determines what they find.
Type 2 Diabetes
Diabetes is rateable, not automatically declinable. The key variables are how long you have had the diagnosis, your most recent A1C (with controlled being generally under 7.5%, well-controlled under 7.0%), whether you have any diabetic complications (neuropathy, retinopathy, nephropathy), and what other medications you take. A GLP-1 user with well-controlled type 2 diabetes and a clean A1C trend is an approvable case at most major carriers — often at standard rates, sometimes at substandard rates, but rarely at outright decline. For more detail on this specific situation, see our guide on life insurance with diabetes in 2026.
Obesity Without Other Conditions
If you are taking a GLP-1 for obesity as a standalone condition — no diabetes, no diagnosed cardiovascular disease — your underwriting picture is generally more straightforward. The weight-related rating will depend on your BMI at the time of the exam (or at the time of accelerated underwriting data collection). The medication itself is not a significant negative. The question is your actual weight, your blood pressure, and your lipid panel.
Cardiovascular Risk Reduction
Following the FDA label change for Wegovy that added cardiovascular risk reduction as an indication, some patients are being prescribed GLP-1 medications specifically for heart disease risk management. This is the most complex underwriting situation because it signals existing cardiovascular concern. In these cases, underwriters will look closely at the full cardiac workup — EKG results, stress test history, echocardiogram findings — before rating the application.
How to Frame Your Application for the Best Possible Outcome
The approach you take to the application matters as much as your actual health profile. Several principles apply specifically to GLP-1 users:
- Disclose everything. Concealing your GLP-1 prescription, or failing to disclose the underlying condition, is the most common and most consequential mistake applicants make. Life insurance policies contain a two-year contestability clause. If you die within two years and the insurer discovers undisclosed health information, they can deny the claim entirely. Full disclosure protects you and your family.
- Bring your lab work. Go into your application with a recent (within six months) print of your relevant labs: A1C if diabetic, fasting glucose, blood pressure readings, LDL and total cholesterol, and current BMI. An underwriter who can see an improving trend in your numbers is in a fundamentally different position than one working from a diagnosis code alone.
- Demonstrate medication compliance. Consistent prescription refills are visible in your pharmacy history and serve as proxy evidence that the treatment is ongoing and managed. A file showing frequent missed refills or dosage changes can signal instability to an underwriter.
- Do not stack formal denials. Every formal application you submit is recorded by the MIB and visible to subsequent carriers. If you apply blindly to five companies and get denied by three, the remaining two see that history. Work with an impaired risk specialist who submits informal inquiries to carriers before any formal application is filed.
- Time it correctly. If you started your GLP-1 medication recently and have not yet shown a stable improvement trend, waiting six to twelve months before applying often produces meaningfully better results.
What If You Are Denied?
A denial from one carrier is not a verdict on your insurability. It is one carrier’s underwriting manual as applied to your file on a specific date. Carrier manuals differ — sometimes significantly — on how they rate the same condition. An impaired risk specialist can identify which carrier is currently most favourable for your specific health profile and submit informal inquiries to get a sense of the outcome before anything formal is filed.
If traditional underwriting genuinely is not available to you right now, two alternatives exist:
Simplified issue life insurance asks a short set of health questions (typically 10–15 yes/no questions rather than a full medical history) and does not require a medical exam. You can be declined on simplified issue for specific conditions, but the threshold for decline is substantially higher than traditional underwriting. Coverage amounts are usually available up to $500,000.
Guaranteed issue life insurance — such as Mutual of Omaha’s final expense products — accepts all applicants regardless of health history. There are no medical questions and no exam. Coverage amounts are limited (typically $2,000–$25,000) and premiums are higher than traditional policies, but coverage is guaranteed. This is the safety net that ensures no one ends up completely uninsurable.
